CIMAvax EGF ( EGF-P64K ) vaccine for the treatment of non- small-cell lung cancer[J].Expert Rev Vaccines, 2015, 14 ( 10 ) : 1303-1311.Crombet Ramos, Tania,Camilo Rodriguez,etc.CIMAvax EGF (EGF-P64K) vaccine for the treatment of non-small-cell lung cancer[J].2015,10(10)....
The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical ...
A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The ...
P64k肿瘤疫苗免疫原性表皮生长因子(epidemal growth factor,EGF)的相对分子质量(Mr)为6000,由53个氨基酸组成;是具有酪氨酸激酶活性的表皮生长因子受体(epidemal growth factor receptor,EGFR)的主要配体,而EGFR在多种上皮源肿瘤中过表达[1-4].EGF可以通过自分泌和旁分泌进入组织内与EGFR单体结合,促使其结构改变后与...
The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical ...